4 Patient access schemes, commercial access agreements and flexible pricing | Guide to the processes of technology appraisal | Guidance | NICE
![Current and future evolution of commercial patient access scheme arrangements in England - Remap Consulting Current and future evolution of commercial patient access scheme arrangements in England - Remap Consulting](https://remapconsulting.com/wp-content/uploads/2023/01/Current-and-future-evolution-of-commercial-patient-access-scheme-arrangements-in-England-2019.png)
Current and future evolution of commercial patient access scheme arrangements in England - Remap Consulting
![PDF] Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods | Semantic Scholar PDF] Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c903013d0bf734461ef7495d5c60ec3371bc7caa/2-Figure1-1.png)
PDF] Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods | Semantic Scholar
Carl Boswell - Programme Manager for the Patient Access Scheme Liaison Unit (PASLU) & Commercial Liaison Team (CLT) - NICE - National Institute for Health and Care Excellence | LinkedIn
![Peter Davis on X: "#dcvax $nwbo #gbm I came across this article from 2014 written after announcement that DCVax had become the first product to enter the UK's 'early access to investigational Peter Davis on X: "#dcvax $nwbo #gbm I came across this article from 2014 written after announcement that DCVax had become the first product to enter the UK's 'early access to investigational](https://pbs.twimg.com/media/GF9BcDmWcAAjoLD.png)
Peter Davis on X: "#dcvax $nwbo #gbm I came across this article from 2014 written after announcement that DCVax had become the first product to enter the UK's 'early access to investigational
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Technology appraisals Patient access scheme submission template
![The Use of Risk-Sharing Agreements to Manage Costs, Mitigate Risk, and Improve Value for Pharmaceutical Products The Use of Risk-Sharing Agreements to Manage Costs, Mitigate Risk, and Improve Value for Pharmaceutical Products](https://d148x66490prkv.cloudfront.net/hmp_ln/inline-images/Table%201_1.png?VersionId=uig7X7bA5g7p7TSF.3KSIZAkqRMNxyT0)
The Use of Risk-Sharing Agreements to Manage Costs, Mitigate Risk, and Improve Value for Pharmaceutical Products
![Figure D1: Typology of Performance-based Patient Access Schemes in the UK | Download Scientific Diagram Figure D1: Typology of Performance-based Patient Access Schemes in the UK | Download Scientific Diagram](https://www.researchgate.net/profile/Ruth-Lopert/publication/299566111/figure/fig2/AS:614158278066189@1523438152899/Figure-D2-Different-types-of-performance-based-reimbursement_Q320.jpg)